SLC3A2: Potential Drug Target Or Biomarker (G6520)

Target Name: SLC3A2

NCBI ID: G6520

SLC3A2

SLC3A2: Potential Drug Target Or Biomarker

SLC3A2 (4F2hc) is a protein that is expressed in various tissues throughout the body. It is a member of the SLC3A2 family, which is known for its role in intracellular signaling. SLC3A2 has been shown to play a role in a variety of biological processes , including cell signaling, neurotransmission, and pain perception. As a result, SLC3A2 has potential as a drug target or biomarker.

One of the key functions of SLC3A2 is its role in intracellular signaling. SLC3A2 is a transmembrane protein that is involved in the signaling cascade between the cytoskeleton and various intracellular signaling pathways. It is part of the adapter protein family, which includes proteins that play a critical role in the regulation of cell signaling pathways.

SLC3A2 has been shown to be involved in a variety of signaling pathways, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in the regulation of cell growth, differentiation, and inflammation. to play a role in the regulation of TGF-β signaling by interacting with the protein Smad4.

In addition to its role in intracellular signaling, SLC3A2 is also involved in the regulation of extracellular signaling. It is a potent positive regulator of the transcription factor CREB, which is involved in the regulation of gene expression and cell signaling. SLC3A2 has been shown to play a role in the regulation of CREB activity by interacting with the protein p180GTP.

SLC3A2 has also been shown to be involved in the regulation of pain perception. Pain perception is a complex process that is involved in the regulation of multiple physiological processes, including the regulation of pain sensitivity and the modulation of pain perception. SLC3A2 has also been shown to play a role in the regulation of pain perception by interacting with the protein TrPV1.

SLC3A2 has also been shown to play a role in the regulation of neurotransmission. Neurotransmission is the process by which signals are transmitted between neurons, and it is critical for the function of the nervous system. in the regulation of neurotransmission by interacting with the protein neurotrophin (NTN).

In conclusion, SLC3A2 is a protein that is involved in a variety of biological processes. Its role in intracellular signaling, extracellular signaling, and pain perception makes it a potential drug target or biomarker. Further research is needed to fully understand the function of SLC3A2 and its potential as a drug or biomarker.

Protein Name: Solute Carrier Family 3 Member 2

Functions: Component of several heterodimeric complexes involved in amino acid transport (PubMed:11557028, PubMed:9829974, PubMed:9751058, PubMed:10391915, PubMed:10574970, PubMed:11311135, PubMed:30341327). The precise substrate specificity depends on the other subunit in the heterodimer (PubMed:9829974, PubMed:9751058, PubMed:10391915, PubMed:10574970, PubMed:30867591, PubMed:10903140). The complexes function as amino acid exchangers (PubMed:11557028, PubMed:10903140, PubMed:12117417, PubMed:12225859, PubMed:30867591). The heterodimer functions as sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, leucine, histidine, methionine, tryptophan, valine and isoleucine (PubMed:9751058, PubMed:11557028, PubMed:11311135, PubMed:11564694, PubMed:12117417, PubMed:12225859, PubMed:25998567, PubMed:30867591, PubMed:30341327). The heterodimer with SLC7A5/LAT1 mediates the uptake of L-DOPA (By similarity). The heterodimer formed by SLC3A2 and SLC7A6 or SLC3A2 and SLC7A7 mediates the uptake of dibasic amino acids (PubMed:9829974, PubMed:10903140). The heterodimer with SLC7A5/LAT1 mediates the transport of thyroid hormones diiodothyronine (T2), triiodothyronine (T3) and thyroxine (T4) across the cell membrane (PubMed:11564694, PubMed:12225859). The heterodimer with SLC7A5/LAT1 is involved in the uptake of toxic methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes (PubMed:12117417). When associated with LAPTM4B, the heterodimer with SLC7A5/LAT1 is recruited to lysosomes to promote leucine uptake into these organelles, and thereby mediates mTORC1 activation (PubMed:25998567). The heterodimer with SLC7A5/LAT1 may play a role in the transport of L-DOPA across the blood-brain barrier (By similarity). The heterodimer formed by SLC3A2 and SLC7A5/LAT1 or SLC3A2 and SLC7A8/LAT2 is involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane (PubMed:15769744). The heterodimer with SLC7A10 translocates small neutral L- and D-amino acids across the plasma membrane. SLC3A2-SLC7A10 preferentially mediates exchange transport, but can also operate via facilitated diffusion (By similarity). Together with ICAM1, regulates the transport activity of SLC7A8/LAT2 in polarized intestinal cells by generating and delivering intracellular signals (PubMed:12716892). Required for targeting of SLC7A5/LAT1 and SLC7A8/LAT2 to the plasma membrane and for channel activity (PubMed:9751058, PubMed:11311135, PubMed:30867591). Plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine (PubMed:14603368). May mediate blood-to-retina L-leucine transport across the inner blood-retinal barrier (By similarity)

The "SLC3A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC3A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets